Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6902756 | 0.80 | CYP2C19 (0.46) | LMNAMCL1TSHRHSP90AA1 | |
| SCHEMBL18477609 | 0.80 | LMNA (0.43) | LMNAPAOXNAMPTPOLBMCL1 | |
| SCHEMBL13123495 | 0.78 | LMNA (0.41) | LMNAPAOXNAMPTPOLBMCL1 | |
| SCHEMBL12791496 | 0.77 | PAOX (0.55) | LMNAPAOXHDAC6TSHR | |
| SCHEMBL2742896 | 0.77 | — | — | |
| SCHEMBL2527724 | 0.77 | — | — | |
| SCHEMBL12847701 | 0.76 | CA12 (0.46) | LMNAPAOXHDAC6 | |
| SCHEMBL5909180 | 0.75 | LMNA (0.57) | LMNANAMPTPOLBMCL1HDAC1 | |
| SCHEMBL7753090 | 0.75 | LMNA (0.57) | LMNANAMPTPOLBMCL1HDAC1 | |
| Hydrochloric Acid SCHEMBL6044378 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | LMNA 139/4885PAOX 3964/4885NAMPT 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.